Antigenic variation in Cryptococcus neoformans: In vitro and in vivo selection

Wendy Cleare, Arturo Casadevall

Research output: Contribution to journalArticle

Abstract

C. neoformans has a polysaccharide capsule that is a virulence factor. Capsulebinding antibodies can mediate protection against infection. The murine monoclonal antibody (mAb 2H1) is representative of a class of antibodies elicited by a polysaccharide-protein conjugate vaccine which are being developed as potential therapeutic agents. C. neoformans infections are chronic and often incurable in patients with impaired immunity. This raises concern about the possibility of antigenic changes during infection and the potential of antibody-based therapies to select for new antigenic variants. To investigate this question we studied the stability of the epitope defined by the protective mAb 2H1 in vivo and in vitro. In vivo experiments were done by serially passaging a colony of C. neoformans in mice given mAb 2H1. In vitro studies were done by selecting for yeast cells which did not agglutinate in the presence of mAb 2H1. The initial and passaged isolates were studied by karyotype analysis, indirect immunofluorescence, FACS and agglutination endpoint. The results indicate: 1) the epitope defined by mAb 2H1 is found in C neoformans after 5 serial passages in mice treated with mAb, suggesting stability in vivo despite antibody selection; 2) variants with markedly altered mAb 2H1 epitope localization can be selected in vitro by recovering yeast that fail to agglutinate; 3) mAb 2H1 is not opsonic for some of these variants; 4) there is considerable variation in mAb 2H1 epitope content and localization within a given C. neoformans strain. The results indicate that, under certain circumstances, mAb 2H1 can select for C. neoformans variants with altered capsular epitope phenotype and this is an important consideration in the design of antibody-based strategies for the prevention and therapy of cryptococcal infection.

Original languageEnglish (US)
Pages (from-to)379
Number of pages1
JournalClinical Infectious Diseases
Volume25
Issue number2
StatePublished - 1997
Externally publishedYes

Fingerprint

Antigenic Variation
Cryptococcus neoformans
Epitopes
Antibodies
Infection
Polysaccharides
Yeasts
Serial Passage
Conjugate Vaccines
Immunoglobulin Isotypes
Agglutination
Virulence Factors
Indirect Fluorescent Antibody Technique
Karyotype
Capsules
Immunity
Therapeutics
Monoclonal Antibodies
In Vitro Techniques
Phenotype

ASJC Scopus subject areas

  • Immunology

Cite this

Antigenic variation in Cryptococcus neoformans : In vitro and in vivo selection. / Cleare, Wendy; Casadevall, Arturo.

In: Clinical Infectious Diseases, Vol. 25, No. 2, 1997, p. 379.

Research output: Contribution to journalArticle

@article{45c3f7618333498b882da1e9204a4ece,
title = "Antigenic variation in Cryptococcus neoformans: In vitro and in vivo selection",
abstract = "C. neoformans has a polysaccharide capsule that is a virulence factor. Capsulebinding antibodies can mediate protection against infection. The murine monoclonal antibody (mAb 2H1) is representative of a class of antibodies elicited by a polysaccharide-protein conjugate vaccine which are being developed as potential therapeutic agents. C. neoformans infections are chronic and often incurable in patients with impaired immunity. This raises concern about the possibility of antigenic changes during infection and the potential of antibody-based therapies to select for new antigenic variants. To investigate this question we studied the stability of the epitope defined by the protective mAb 2H1 in vivo and in vitro. In vivo experiments were done by serially passaging a colony of C. neoformans in mice given mAb 2H1. In vitro studies were done by selecting for yeast cells which did not agglutinate in the presence of mAb 2H1. The initial and passaged isolates were studied by karyotype analysis, indirect immunofluorescence, FACS and agglutination endpoint. The results indicate: 1) the epitope defined by mAb 2H1 is found in C neoformans after 5 serial passages in mice treated with mAb, suggesting stability in vivo despite antibody selection; 2) variants with markedly altered mAb 2H1 epitope localization can be selected in vitro by recovering yeast that fail to agglutinate; 3) mAb 2H1 is not opsonic for some of these variants; 4) there is considerable variation in mAb 2H1 epitope content and localization within a given C. neoformans strain. The results indicate that, under certain circumstances, mAb 2H1 can select for C. neoformans variants with altered capsular epitope phenotype and this is an important consideration in the design of antibody-based strategies for the prevention and therapy of cryptococcal infection.",
author = "Wendy Cleare and Arturo Casadevall",
year = "1997",
language = "English (US)",
volume = "25",
pages = "379",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Antigenic variation in Cryptococcus neoformans

T2 - In vitro and in vivo selection

AU - Cleare, Wendy

AU - Casadevall, Arturo

PY - 1997

Y1 - 1997

N2 - C. neoformans has a polysaccharide capsule that is a virulence factor. Capsulebinding antibodies can mediate protection against infection. The murine monoclonal antibody (mAb 2H1) is representative of a class of antibodies elicited by a polysaccharide-protein conjugate vaccine which are being developed as potential therapeutic agents. C. neoformans infections are chronic and often incurable in patients with impaired immunity. This raises concern about the possibility of antigenic changes during infection and the potential of antibody-based therapies to select for new antigenic variants. To investigate this question we studied the stability of the epitope defined by the protective mAb 2H1 in vivo and in vitro. In vivo experiments were done by serially passaging a colony of C. neoformans in mice given mAb 2H1. In vitro studies were done by selecting for yeast cells which did not agglutinate in the presence of mAb 2H1. The initial and passaged isolates were studied by karyotype analysis, indirect immunofluorescence, FACS and agglutination endpoint. The results indicate: 1) the epitope defined by mAb 2H1 is found in C neoformans after 5 serial passages in mice treated with mAb, suggesting stability in vivo despite antibody selection; 2) variants with markedly altered mAb 2H1 epitope localization can be selected in vitro by recovering yeast that fail to agglutinate; 3) mAb 2H1 is not opsonic for some of these variants; 4) there is considerable variation in mAb 2H1 epitope content and localization within a given C. neoformans strain. The results indicate that, under certain circumstances, mAb 2H1 can select for C. neoformans variants with altered capsular epitope phenotype and this is an important consideration in the design of antibody-based strategies for the prevention and therapy of cryptococcal infection.

AB - C. neoformans has a polysaccharide capsule that is a virulence factor. Capsulebinding antibodies can mediate protection against infection. The murine monoclonal antibody (mAb 2H1) is representative of a class of antibodies elicited by a polysaccharide-protein conjugate vaccine which are being developed as potential therapeutic agents. C. neoformans infections are chronic and often incurable in patients with impaired immunity. This raises concern about the possibility of antigenic changes during infection and the potential of antibody-based therapies to select for new antigenic variants. To investigate this question we studied the stability of the epitope defined by the protective mAb 2H1 in vivo and in vitro. In vivo experiments were done by serially passaging a colony of C. neoformans in mice given mAb 2H1. In vitro studies were done by selecting for yeast cells which did not agglutinate in the presence of mAb 2H1. The initial and passaged isolates were studied by karyotype analysis, indirect immunofluorescence, FACS and agglutination endpoint. The results indicate: 1) the epitope defined by mAb 2H1 is found in C neoformans after 5 serial passages in mice treated with mAb, suggesting stability in vivo despite antibody selection; 2) variants with markedly altered mAb 2H1 epitope localization can be selected in vitro by recovering yeast that fail to agglutinate; 3) mAb 2H1 is not opsonic for some of these variants; 4) there is considerable variation in mAb 2H1 epitope content and localization within a given C. neoformans strain. The results indicate that, under certain circumstances, mAb 2H1 can select for C. neoformans variants with altered capsular epitope phenotype and this is an important consideration in the design of antibody-based strategies for the prevention and therapy of cryptococcal infection.

UR - http://www.scopus.com/inward/record.url?scp=33748133850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748133850&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748133850

VL - 25

SP - 379

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 2

ER -